In this issue:
Clinical practice guideline on immunotherapy for melanoma
Durable clinical benefit to adjuvant mRNA vaccine in resected melanoma
Lifileucel approved in the US for post-PD-1 unresectable melanoma
Pre-treatment with fenofibrate may boost cell-based therapy in melanoma
Tebentafusp confers a durable survival benefit in HLA-A*02:01– positive uveal melanoma
Is tebentafusp superior to nivolumab + ipilimumab in metastatic uveal melanoma?
Emotional distress blunts response to neoadjuvant immunotherapy
PBS listings
FDA approves phase 3 testing of TLPO vaccine for melanoma
SEACRAFT-2 to assess naporafenib + trametinib for refractory NRAS-mutant disease
Real-world effectiveness of tebentafusp
Darovasertib + crizotinib promising for uveal melanoma
COVID-19 resources
Conferences, workshops and CPD
Please login below to download this issue (PDF)